{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:26:01Z","timestamp":1793013961214,"version":"4.5.0"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective.<\/jats:bold>\n                    Micromegaly describes a subgroup of patients with clinically evident acromegaly and elevated insulin-like growth factor I (IGF-I) with apparently normal basal growth hormone (bGH) and often a glucose-suppressed growth hormone (GH) of &lt;1 ng\/mL at diagnosis. It is controversial whether this condition is a distinct clinical entity or a classic acromegaly in early stages. The aim of the present article was to characterize the prevalence, clinical and biochemical characteristics, and therapeutic outcomes of micromegaly.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.<\/jats:bold>\n                    A retrospective study of patients with an acromegaly followed \u22651 year at a tertiary center from 1995 to 2019. Patients without IGF-I or GH measurements at diagnosis were excluded. At diagnosis, bGH was considered normal if &lt;2 ng\/mL.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    From 74 patients with acromegaly, 6 (8.1%) had normal bGH levels. There was no difference in the gender distribution, median diagnostic delay, and follow-up time between patients with normal bGH and elevated bGH. Patients with normal bGH were significantly older at time of the first acromegalic manifestation and diagnosis they had significantly lower nadir post-glucose GH and IGF-I levels, and tended to have a higher prevalence of obesity than patients with the elevated bGH. The frequency of acromegalic symptoms, signs, and other comorbidities than obesity was similar between groups. Five patients (83.3%) with normal bGH presented microadenomas. Post-operative remission and outcomes at last visit were comparable between patients with or without normal bGH.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.<\/jats:bold>\n                    Normal bGH acromegaly is relatively uncommon in our patients. These patients showed differentiating characteristics from the classical acromegaly with elevated bGH. Further studies are needed to extend the knowledge about its clinical behavior, therapeutic outcomes, morbidity, and mortality.\n                  <\/jats:p>","DOI":"10.2478\/enr-2022-0010","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T14:38:51Z","timestamp":1651329531000},"page":"87-94","source":"Crossref","is-referenced-by-count":3,"title":["Characteristics and treatment outcomes of micromegaly \u2013 acromegaly with apparently normal basal GH: A retrospective study and literature review"],"prefix":"10.2478","volume":"56","author":[{"given":"Isabel","family":"Inacio","sequence":"first","affiliation":[{"name":"Endocrinology Department , Centro Hospitalar do Baixo Vouga , Aveiro , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Centro Hospitalar Universitario do Porto , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Amado","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Centro Hospitalar Universitario do Porto , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Benido","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Centro Hospitalar Universitario do Porto , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Neurosurgery Department , Centro Hospitalar Universitario do Porto , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Dores","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Centro Hospitalar Universitario do Porto , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Amaral","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Centro Hospitalar Universitario do Porto , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Helena","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Centro Hospitalar Universitario do Porto , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"2026042722155481478_j_enr-2022-0010_ref_001","doi-asserted-by":"crossref","unstructured":"Akirov A, Masri-Iraqi H, Dotan I, Shimon I. The biochemical diagnosis of acromegaly. J Clin Med 10, 1147, 2021.10.3390\/jcm10051147796711633803429","DOI":"10.3390\/jcm10051147"},{"key":"2026042722155481478_j_enr-2022-0010_ref_002","doi-asserted-by":"crossref","unstructured":"Amodru V, Petrossians P, Colao A, Delemer B, Maione L, Neggers SJCMM, Decoudier B, Kamenicky P, Castinetti F, Hana V, Pivonello R, Carvalho D, Brue T, Beckers A, Chanson P, Cuny T. Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database. Endocrine 70, 134\u2013142, 2020.10.1007\/s12020-020-02387-132562181","DOI":"10.1007\/s12020-020-02387-1"},{"key":"2026042722155481478_j_enr-2022-0010_ref_003","doi-asserted-by":"crossref","unstructured":"Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburge CJ, Schofl C, Pfeiffer AFH. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93, 1254\u20131262, 2008.10.1210\/jc.2007-208418171702","DOI":"10.1210\/jc.2007-2084"},{"key":"2026042722155481478_j_enr-2022-0010_ref_004","doi-asserted-by":"crossref","unstructured":"Brockmeier SJ, Buchfelder M, Adams EF, Schott W, Fahlbusch R. Acromegaly with normal serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery. Horm Metab Res 24, 392\u2013400, 1992.10.1055\/s-2007-10033421526628","DOI":"10.1055\/s-2007-1003342"},{"key":"2026042722155481478_j_enr-2022-0010_ref_005","doi-asserted-by":"crossref","unstructured":"Butz LB, Sullivan SE, Chandler WF, Barkan AL. Micromegaly: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary 19, 547\u2013551, 2016.10.1007\/s11102-016-0735-027497970","DOI":"10.1007\/s11102-016-0735-0"},{"key":"2026042722155481478_j_enr-2022-0010_ref_006","doi-asserted-by":"crossref","unstructured":"Carosi G, Mangone A, Sala E, Del Sindaco G, Mungari R, Cremaschi A, Ferrante E, Arosio M, Mantovani G. Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study. Eur J Endocrinol 185, 289\u2013297, 2021.10.1530\/EJE-21-0024828490534081617","DOI":"10.1530\/EJE-21-0024"},{"key":"2026042722155481478_j_enr-2022-0010_ref_007","doi-asserted-by":"crossref","unstructured":"Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57, 555\u2013559, 2011.10.1373\/clinchem.2010.15063121285256","DOI":"10.1373\/clinchem.2010.150631"},{"key":"2026042722155481478_j_enr-2022-0010_ref_008","doi-asserted-by":"crossref","unstructured":"Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab, 87, 3537\u20133542, 2002.10.1210\/jcem.87.8.865812161471","DOI":"10.1210\/jcem.87.8.8658"},{"key":"2026042722155481478_j_enr-2022-0010_ref_009","doi-asserted-by":"crossref","unstructured":"Espinosa de Los Monteros AL, Sosa-Eroza E, Gonzalez B, Mendoza V, Mercado M. Prevalence, clinical and biochemical spectrum, and treatment outcome of acromegaly with normal basal GH at diagnosis. J Clin Endocrinol Metab 103, 3919\u20133924, 2018.10.1210\/jc.2018-0111330060172","DOI":"10.1210\/jc.2018-01113"},{"key":"2026042722155481478_j_enr-2022-0010_ref_010","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S. A Pituitary Society update to acromegaly management guidelines. Pituitary 24, 1\u201313, 2021.10.1007\/s11102-020-01091-7786483033079318","DOI":"10.1007\/s11102-020-01091-7"},{"key":"2026042722155481478_j_enr-2022-0010_ref_011","doi-asserted-by":"crossref","unstructured":"Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1 microg\/L in newly diagnosed acromegaly. Pituitary 6, 175\u2013180, 2003.10.1023\/B:PITU.0000023424.72021.e2","DOI":"10.1023\/B:PITU.0000023424.72021.e2"},{"key":"2026042722155481478_j_enr-2022-0010_ref_012","doi-asserted-by":"crossref","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Dis 21, 667\u2013678, 2020.10.1007\/s11154-020-09588-z794278332914330","DOI":"10.1007\/s11154-020-09588-z"},{"key":"2026042722155481478_j_enr-2022-0010_ref_013","unstructured":"Gomes V, Matos T, Ferreira F, Nobre E, Reis D, Bugalho MJ. Acromegalia com hormona de crescimento normal \u2013 subpopulacao diferente? Rev Portug Endocrinol Diabet Metabol 14, 91\u201392, 2019."},{"key":"2026042722155481478_j_enr-2022-0010_ref_014","doi-asserted-by":"crossref","unstructured":"Katznelson L, Laws Jr. ER, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99, 3933\u20133951, 2014.10.1210\/jc.2014-270025356808","DOI":"10.1210\/jc.2014-2700"},{"key":"2026042722155481478_j_enr-2022-0010_ref_015","doi-asserted-by":"crossref","unstructured":"Kruse CPS, Cottrill DA, Kopchick JJ. Could calgranulins and advanced glycated end products potentiate acromegaly pathophysiology? Growth Horm IGF Res 46-47, 1\u20134, 2019.10.1016\/j.ghir.2019.04.00231071497","DOI":"10.1016\/j.ghir.2019.04.002"},{"key":"2026042722155481478_j_enr-2022-0010_ref_016","doi-asserted-by":"crossref","unstructured":"Machado EO, Taboada GF, Neto LV, van Haute FR, Correa LL, Balarini GA, Shrank Y, Goulart M, Gadelha MR. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18, 389\u2013393, 2008.10.1016\/j.ghir.2008.02.00118348909","DOI":"10.1016\/j.ghir.2008.02.001"},{"key":"2026042722155481478_j_enr-2022-0010_ref_017","doi-asserted-by":"crossref","unstructured":"Ribeiro-Oliveira Jr. A, Faje AT, Barkan AL. Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol 164, 17\u201312, 2011.10.1530\/EJE-10-074420926592","DOI":"10.1530\/EJE-10-0744"},{"key":"2026042722155481478_j_enr-2022-0010_ref_018","doi-asserted-by":"crossref","unstructured":"Schilbach K, Strasburger CJ, Bidlingmaier M. Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 20, 33\u201345, 2017.10.1007\/s11102-017-0792-z28168377","DOI":"10.1007\/s11102-017-0792-z"},{"key":"2026042722155481478_j_enr-2022-0010_ref_019","doi-asserted-by":"crossref","unstructured":"Schilbach, K, Gar C, Lechner A, Nicolay SS, Schwerdt L, Haenelt M, Dal J, Jorgensen J-OL, Stormann S, Schopohl J, Bidlingmaier M. Determinants of the growth hormone nadir during oral glucose tolerance test in adults. Eur J Endocrinol 181, 55\u201367, 2019.10.1530\/EJE-19-013931096183","DOI":"10.1530\/EJE-19-0139"},{"key":"2026042722155481478_j_enr-2022-0010_ref_020","doi-asserted-by":"crossref","unstructured":"Subbarayan SK, Fleseriu M, Gordon MB, Brzana JA, Kennedy L, Faiman C, Hatipoglu BA, Prayson RA, Delashaw JB, Weil RJ, Hamrahian AH. Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone. Endocr Pract 18, 817\u2013825, 2012.10.4158\/EP11324.OR22784832","DOI":"10.4158\/EP11324.OR"},{"key":"2026042722155481478_j_enr-2022-0010_ref_021","doi-asserted-by":"crossref","unstructured":"Yakar S, Isaksson O. Regulation of skeletal growth and mineral acquisition by the GH\/IGF-1 axis: Lessons from mouse models. Growth Horm IGF Res 28, 26\u201342, 2016.10.1016\/j.ghir.2015.09.004480978926432542","DOI":"10.1016\/j.ghir.2015.09.004"}],"container-title":["Endocrine Regulations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/enr-2022-0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:47:01Z","timestamp":1777348021000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/enr-2022-0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,30]]},"published-print":{"date-parts":[[2022,4,1]]}},"alternative-id":["10.2478\/enr-2022-0010"],"URL":"https:\/\/doi.org\/10.2478\/enr-2022-0010","relation":{},"ISSN":["1336-0329"],"issn-type":[{"value":"1336-0329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}